Treatment for Injecting Drug Users: Antiretrovirals and Beyond MOSA03
Type:
Satellite Back
Venue: Skills Building Room 6
Interpretation: None
Time: 07:00 - 08:30
Code: MOSA03

Organiser:
International Harm Reduction Development Program

Supported by:
Open Society Institute

Description / Focus:
This breakfast session will launch Delivering HIV Care and Treatment for People Who Use Drugs: Lessons from Research and Practice," the Open Society Institute’s new publication on treatment for IDUs. Michel Kazatchkine and Joep Lange (France and Netherlands) will offer comments on lessons learned and obstacles on the way forward, and Alexandra Volgina (Russia) will offer comments on HIV treatment access and harm reduction, peer counseling, and patient outreach models in Russia, followed by discussion. Ten percent of the world’s HIV cases are among injecting drug users (IDUs). Yet in nearly all countries—including those where they comprise a significant majority of all cases--IDUs have been disproportionately less likely to have access to ARV treatment and other medical care. In many developing/transitional countries with injection-driven epidemics, ARV has been provided to drug users last if it has been offered to them at all, despite evidence that with appropriate support IDUs can achieve adherence and treatment outcomes comparable to those of any other patient groups. "

Click here to see the webcast of this session on Kaiser Networks web site

    Presentations in this session:
Treatment Access for IDUs: Lessons Learned and the Way Forward
Michel Kazatchkine and Joep Lange (France and Netherlands)
Harm Reduction, Peer Counseling, and Patient Outreach: The GLOBUS Model in Russia
Alexandra Volgina (Russia)




Audio files:
  1. English audio file (mp3 format, 38.4 MB)

Rapporteur report

KC 3: Intensifying involvement of affected individuals and communities report by Konstantin Lezhentsev

This satellite was focused on discussing main barriers and key challenges for equal access to HIV care and treatment for IDUs. It was also aimed at presenting best models and practices on how to effectively deliver care for IDUs, organize effective ARV utilization, adherence support in an integrated and comprehensive model of IDU care.

Joep Lange addressed the global issue of fear that many doctors still have in proposing treatment for IDUs, establishing their own criteria of who is eligible to treatment and who is not. Dr Lange also underlined that equal access to ARV for IDUs is not only a humanitarian issue but also important to effectively combat the epidemic. Adherence rates among most IDUs are the same and sometimes even better than in other categories of patients.

Sasha Volgina, activist and peer expert from Russia, presented a model on how PLWHAs/IDU community activism can lead to radical changes in national policy. The key problems are still constant interruptions of ARVs, lack of patient outreach and effective adherence support, treatment literacy work, Harm Reduction integration into treatment. Repressive drug policies, police harassment an illegal status of substitution treatment in Russia are still key barriers for access to prevention and treatment.

 

Michel Kazatchkine made a touching historical overview of his first IDU patient and reminded that evidence shows that doctors are unable to predict adherence. Mortality in IDU group is higher than in other groups, but it is also proven that it is not linked to the poorer response to HAART but due to co-infection, late HAART initiation and non-HIV related deaths. 20 years  passed since Michel first met his first IDU patient Nestor and he can not believe that we are still advocating for the things that have been proven to be effective decades ago.




    Add this session to your itinerary and back

    Back to the Programme-at-a-Glance



    The organizers reserve the right to amend the programme.

Copyright Notice © IAS Disclaimer